Chris Gabel is an accomplished executive with extensive expertise in the biotechnology and pharmaceutical industries. As the VP of Biology at NodThera Limited, he leverages his deep scientific knowledge and leadership experience to drive the company's research and development efforts in the field of immunology and inflammation.
Experience Summary
Current Role
As the VP of Biology at NodThera Limited since 2018, Chris is responsible for overseeing the company's biology and preclinical research programs. He leads a team of scientists focused on developing innovative therapeutics targeting the NLRP3 inflammasome, a key mediator of inflammatory diseases. Under his guidance, NodThera has advanced several promising drug candidates and expanded its pipeline to address unmet medical needs.
Career Progression
Prior to joining NodThera, Chris held various leadership positions in the industry. He served as the Chief Scientific Officer at Resolve Therapeutics from 2012 to 2015, where he played a pivotal role in the development of novel immunomodulatory therapies. Additionally, he was the Principal at his own consulting firm, Chris Gabel LLC, from 2012 to 2018, providing strategic insights and technical expertise to biotechnology companies.
Earlier in his career, Chris held executive positions at Amgen, where he was the Executive Director, and at Pfizer, where he was a Senior Scientist and Research Advisor in the Inflammation Pharmacology department.
Academic Background
Chris holds a Ph.D. in Molecular Biology from the University of Washington, where he specialized in immunology and inflammation research. His academic achievements include numerous publications in peer-reviewed journals and invited presentations at industry conferences.
Areas of Expertise
- Immunology and inflammation biology
- Drug discovery and development
- Preclinical research and translational science
- Team leadership and strategic planning
- Regulatory affairs and clinical development
Professional Impact
Throughout his career, Chris has made significant contributions to advancing the understanding and treatment of inflammatory diseases. His work has led to the identification of novel therapeutic targets and the development of several drug candidates that have progressed through clinical trials. His expertise and leadership have been instrumental in driving the success of the organizations he has been associated with.
Conclusion
With his extensive experience, deep scientific knowledge, and proven track record of success, Chris Gabel is a valued leader in the biotechnology industry. As the VP of Biology at NodThera Limited, he continues to make significant contributions to the development of innovative therapies that address critical unmet medical needs.
